Tvardi Therapeutics (NASDAQ:TVRD) Rating Lowered to Strong Sell at Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

Other analysts have also recently issued reports about the stock. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, July 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a report on Wednesday, July 8th. BTIG Research reduced their target price on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tvardi Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tvardi Therapeutics Stock Performance

Shares of TVRD stock opened at $1.80 on Friday. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The firm has a market capitalization of $24.01 million, a PE ratio of -0.65 and a beta of 0.39. The stock’s 50-day simple moving average is $2.30 and its 200-day simple moving average is $3.02.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Sell-side analysts forecast that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

Several hedge funds have recently bought and sold shares of TVRD. JPMorgan Chase & Co. purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tvardi Therapeutics during the second quarter worth $43,000. Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics during the second quarter worth $80,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics during the second quarter worth $92,000. Finally, Arax Advisory Partners grew its position in Tvardi Therapeutics by 277.2% during the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after buying an additional 6,173 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.